Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report
| Autor: | Betul Ogut, Nilsel Ilter, Elçin Akdas, Ozlem Erdem |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) business.industry viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus diseases Dermatology medicine.disease World health Vaccination 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Infectious Diseases 030220 oncology & carcinogenesis Pityriasis rosea Inactivated vaccine Medicine Letters to the Editor business Adverse effect Letter to the Editor |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology |
| ISSN: | 1468-3083 0926-9959 |
| DOI: | 10.1111/jdv.17316 |
| Popis: | According to official data published by the World Health Organization, more than 100 million cases worldwide have been confirmed to be infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing over two million deaths. The CoronaVac vaccine, an inactivated vaccine candidate against COVID-19 containing inactivated SARS-CoV-2, is a Chinese vaccine developed by Sinovac Life Sciences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text